Security key
74019P108
- Security type / class
- Equity / COM
- Total 13F shares
- 34,890,365
- Total 13F value
- $12,735,764
- Share change
- +2,349,516
- SEC-reported price per share
- $0.36
- Number of holders
- 60
- Value change
- +$914,125
- Number of buys
- 27
- Number of sells
- 25
Report period
Q4 2023
Institutions
60
Top holders
10
DTIL full security history
Ownership snapshot
Full 13F holder table
PRECISION BIOSCIENCES INC SEC filings
PRECISION BIOSCIENCES INC company facts
Broader feeds
Ownership snapshot
Top reported holders of DTIL - PRECISION BIOSCIENCES INC - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
NOVARTIS PHARMA AG
Disclosed value leader
NOVARTIS PHARMA AG
Comparable rows
0/15
Latest evidence
30 Sep 2023
3/4/5
13F
Highest disclosed value: $4,590,753
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
NOVARTIS PHARMA AG has the largest disclosed position value at $4.59M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens NOVARTIS PHARMA AG's linked filing trail.
Disclosed position value
Top 5
NOVARTIS PHARMA AG
$4.59M
Capital World Investors
$2.29M
VANGUARD GROUP INC
$1.6M
Derek Jantz
$1.51M
ACADIAN ASSET MANAGEMENT LLC
$1.07M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| NOVARTIS PHARMA AG |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,590,753
12,407,440 shares
|
— | 15 Jun 2022 |
| Capital World Investors |
13F
Company
|
—
denominator unverified
|
$2,291,844
6,715,043 shares
|
— | 30 Sep 2023 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$1,601,747
4,693,076 shares
|
— | 30 Sep 2023 |
| Derek Jantz |
3/4/5
Chief Scientific Officer, Director
|
—
mixed-class rows
|
$1,509,439
4,079,565 shares
mixed-class rows
|
— | 07 Jun 2022 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$1,073,000
3,148,243 shares
|
— | 30 Sep 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$1,069,603
3,133,909 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
60
Shares
34,890,365
Rows available
60
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
73
Q4 2023 holders
60
Holder diff
-13
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|